Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS

Plain-language summary

This study examines genetic susceptibility to malignant pleural mesothelioma by looking at inherited (germline) gene variations. It includes people aged 18 and older in two groups: patients diagnosed with malignant pleural mesothelioma (Cohort A) and healthy individuals formerly exposed to asbestos (Cohort B). Conducted by Fondazione IRCCS Policlinico San Matteo di Pavia, this study without an assigned phase is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Start date

6/15/2023

Estimated completion

12/31/2025

Countries

Italy

Related genes

Locations

• Pavia, Italy
• Pavia, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria Cohort A:

* Patient with a documented diagnosis of MPM (any disease stage and independently from chemo line treatment)
* Age ≥ 18 years (there is no upper age limit).
* Patient who gives their informed consent to participate in the study

Exclusion Criteria Cohort A:

* No exclusion criteria

Inclusion Criteria Cohort B:

* Former asbestos exposed healthy subjects
* Age ≥ 18 years (there is no upper age limit).
* Subject who gives their informed consent to participate in the study

Exclusion Criteria Cohort B:

* No exclusion criteria